Adverse reactions in the treatment of patients with non-tuberculous pulmonary mycobacteriosis. Source: Virtual Congress 2021 – Advances in diagnosis, treatment and clinical management of nontuberculous mycobacterial disease Year: 2021
Adverse events during treatment for latent tuberculosis infection Source: Annual Congress 2011 - Treatment of tuberculosis and adverse drug reactions Year: 2011
When is an infectious disease? The clinical spectrum of nontuberculous mycobacterial pulmonary disease Source: International Congress 2019 – New guidelines for treatment of nontuberculous mycobacterial pulmonary disease Year: 2019
A possible association between breast cancer, bronchiectasis and nontuberculous mycobacterial (NTM) lung disease Source: International Congress 2014 – Resistance, bacteriological profile and comorbidities in respiratory infections Year: 2014
Treatment of pulmonary NTM infection: can it be done? Source: Annual Congress 2007 - Nontuberculous mycobacteria (NTM): a slow-growing challenge Year: 2007
Outcomes of patients undergoing treatment for non-tuberculous mycobacteria lung disease Source: International Congress 2019 – Clinical investigations of non-TB mycobacterial infection Year: 2019
Adverse events in the treatment of multidrug-resistant tuberculosis Source: Annual Congress 2011 - Treatment of tuberculosis and adverse drug reactions Year: 2011
The impact of new ATS/IDSA guideline for nontuberculous mycobacterial disease on the diagnosis of nontuberculous mycobacterial lung disease in Korea Source: Annual Congress 2008 - Aetiology of respiratory infections: mycobacteria and fungi Year: 2008
Patient reported outcomes for non-tuberculous mycobacterial disease Source: Eur Respir J, 55 (1) 1902204; 10.1183/13993003.02204-2019 Year: 2020
Non-tuberculous mycobacterial lung disease and COPD Source: Eur Respir Monogr 2015; 69: 172-184 Year: 2015
Unresolved issues in treatment outcome definitions for nontuberculous mycobacterial pulmonary disease Source: Eur Respir J, 53 (5) 1801636; 10.1183/13993003.01636-2018 Year: 2019
Cure rates in nontuberculous mycobacterial pulmonary disease Source: International Congress 2019 – Tuberculosis and non-TB mycobacterial infection II Year: 2019
Systemic corticosteroid and inhalation corticosteroid therapy are associated with nontuberculous mycobacterial pulmonary disease Source: International Congress 2015 – Non-tuberculous mycobacteria and molecular microbiology Year: 2015
Clinical analysisof patients with pulmonary nontuberculous mycobacterial disease complicated with pneumothorax Source: Annual Congress 2013 –Non-tuberculous mycobacteria: clinical management Year: 2013
Non-tuberculous mycobacteria – number of drugs and duration of treatment – does it matter? Source: International Congress 2017 – Bronchiectasis and NTM infections: epidemiology, phenotyping and therapeutic strategies Year: 2017
Nontuberculous mycobacterial disease: an important cause of morbi-mortality in HIV infected subjects Source: Eur Respir J 2003; 22: Suppl. 45, 333s Year: 2003
Nontuberculous mycobacteria in non-HIV patients: epidemiology, treatment and response Source: Eur Respir J 2004; 23: 741-746 Year: 2004
Treatment outcomes of non tuberculous mycobacterial (NTM) pulmonary disease. Multicenter study Source: Virtual Congress 2020 – Non-tuberculous mycobacteria and latent tuberculosis infection Year: 2020
Silica exposure, silicosis, autoimmune diseases, tuberculosis and nontuberculous pulmonary mycobacterial disease Source: International Congress 2016 – Occupational epidemiology Year: 2016